367 related articles for article (PubMed ID: 6342739)
1. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
2. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
6. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
[TBL] [Abstract][Full Text] [Related]
9. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Peter HH; Deutschmann EM; Schultheis W; Deicher H
Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
11. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
Ariyan S; Kirkwood JM; Mitchell MS; Nordlund JJ; Lerner AB; Papac RJ
Surgery; 1982 Sep; 92(3):459-63. PubMed ID: 7112396
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
13. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
14. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
Storm FK; Sparks FC; Morton DL
Surg Gynecol Obstet; 1979 Jul; 149(1):17-21. PubMed ID: 451822
[TBL] [Abstract][Full Text] [Related]
15. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
[TBL] [Abstract][Full Text] [Related]
16. Surgical treatment of malignant melanoma.
Rosenberg SA
Cancer Treat Rep; 1976 Feb; 60(2):159-63. PubMed ID: 769968
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in malignant melanomaa.
Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
[TBL] [Abstract][Full Text] [Related]
19. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
Wätzig V; Knopf B
Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy of malignant melanoma].
Adler A
Harefuah; 1986 Jul; 111(1-2):11-7. PubMed ID: 3781371
[No Abstract] [Full Text] [Related]
[Next] [New Search]
